Funds 5 biomedical technologies with potential for patient benefit,
commercial viability
Two researchers are developing a device to
stabilize newborns being tested for meningitis. Another two are growing human tissue for post heart-attack repair.
Others are focused on solutions aimed at diagnosing or treating diabetes, pulmonary fibrosis and back pain.
Brown
Biomedical Innovations to Impact (BBII) will award each of
those five Brown University faculty research projects up to $100,000 to
translate promising discoveries in biomedical research into product
opportunities that may benefit patients and be commercially viable.
The
five awards culminate the first full award cycle for BBII, a commercial
development program launched by the University’s Division of Biology and
Medicine in collaboration with the Office of Industry Engagement and Commercial
Venturing.
The primary goal of BBII is to help bridge the “valley of death” — the gap between federal funding for research and when private investors are willing to invest — for biomedical research projects led by Brown faculty.
The primary goal of BBII is to help bridge the “valley of death” — the gap between federal funding for research and when private investors are willing to invest — for biomedical research projects led by Brown faculty.
The ultimate aim is to benefit both patients and the economy by launching new products such as therapeutics, diagnostics and medical devices and even startup companies based on Brown research, said Karen Bulock, managing director of BBII.
“BBII
helps to bridge the gap between academic biomedical discoveries and new
products by providing much-needed funding for this type of research,” Bulock
said.
“We look forward to collaborating with the 2019 awardees to further develop their technologies toward real products that can help patients. BBII also offers coaching and project management resources to guide technologies through proof-of-concept into well-defined product opportunities that will attract the attention of industry collaborators and potential investors.”
“We look forward to collaborating with the 2019 awardees to further develop their technologies toward real products that can help patients. BBII also offers coaching and project management resources to guide technologies through proof-of-concept into well-defined product opportunities that will attract the attention of industry collaborators and potential investors.”
The
work of BBII complements Brown’s ongoing efforts to boost innovation in Rhode
Island and is one of five actions outlined in Brown and the
Innovation Economy, a plan debuted in 2018 to expand the
University’s impact on economic growth across the Ocean State. To date,
BBII has been supported by more than $8 million in philanthropic gifts.
The
26 project proposals BBII received were evaluated by an external advisory committee
of industry leaders such as pharmaceutical business developers and venture
capitalists. The committee guided the selection of the winning projects based
on criteria such as potential impact of the product, the market needs and
patentability of the technology, Bulock said.
The
faculty members leading each project will receive initial funding beginning
later this month and additional funds as they meet certain milestones over the
next year. Below is an overview of each of the selected projects.
Developing
an infant lumbar puncture stabilizer
Dr.
Brian Alverson, a professor of pediatrics and medical science and the director
of the Division of Hospital Medicine at Hasbro Children’s Hospital, and Dr.
Ravi D‘Cruz, a teaching fellow in the Warren Alpert Medical School Department
of Pediatrics, will develop and test a positioning device to stabilize feverish
infants less than 60 days old who must undergo a lumbar puncture to test for
meningitis.
Performing lumbar punctures on tiny babies is challenging, yet a good sample of cerebrospinal fluid is critical for determining if antibiotics are necessary as well as the correct antibiotic to use. A device to improve performing lumbar punctures would improve the care of these infants and reduce unnecessary medical costs, Alverson wrote in his application.
Performing lumbar punctures on tiny babies is challenging, yet a good sample of cerebrospinal fluid is critical for determining if antibiotics are necessary as well as the correct antibiotic to use. A device to improve performing lumbar punctures would improve the care of these infants and reduce unnecessary medical costs, Alverson wrote in his application.
Discovering
new drugs to treat metabolic disorders such as obesity and Type 2 diabetes
Dr.
Stephen Helfand, a professor in the Department of Molecular Biology, Cell
Biology and Biochemistry, will work to identify potential drugs to stop a
protein known as INDY, an acronym for the colorfully named “I’m Not Dead Yet”
protein.
Prior research has shown that this protein is important for energy metabolism in animals from flies to humans. These studies suggest that the human version of INDY, found in the liver, is an excellent target for therapeutic interventions of the major metabolic disorders, such as Type 2 diabetes, obesity and hypertension, Helfand wrote in his application. His team will perform a high-throughput screen for small molecule drug candidates to inhibit INDY activity in a test tube.
Prior research has shown that this protein is important for energy metabolism in animals from flies to humans. These studies suggest that the human version of INDY, found in the liver, is an excellent target for therapeutic interventions of the major metabolic disorders, such as Type 2 diabetes, obesity and hypertension, Helfand wrote in his application. His team will perform a high-throughput screen for small molecule drug candidates to inhibit INDY activity in a test tube.
Optimizing
a new drug to treat pulmonary fibrosis
Dr.
Chun Geun Lee, a professor (research) in the Department of Molecular
Microbiology and Immunology, will chemically optimize kasugamycin to make it a
better drug.
Kasugamycin is an antibiotic that has been found to stop the activity of Chitinase 1, which earlier work shows plays a critical role in the lung scarring that causes pulmonary fibrosis.
Lee’s team will focus on making chemical derivatives of kasugamycin that are more effective at preventing and treating lung scarring and have reduced antibacterial activity. This may lead to the development of a new drug that is safe, effective and readily available to patients with pulmonary fibrosis, Lee wrote in his application.
Kasugamycin is an antibiotic that has been found to stop the activity of Chitinase 1, which earlier work shows plays a critical role in the lung scarring that causes pulmonary fibrosis.
Lee’s team will focus on making chemical derivatives of kasugamycin that are more effective at preventing and treating lung scarring and have reduced antibacterial activity. This may lead to the development of a new drug that is safe, effective and readily available to patients with pulmonary fibrosis, Lee wrote in his application.
Growing
human tissues for post-heart-attack repair
Jeffrey
Morgan, a professor in the Department of Molecular Pharmacology, Physiology and
Biotechnology and engineering and Blanche Ip, an assistant professor
(research), in the Department of Molecular Pharmacology, Physiology and
Biotechnology, will use their award to advance their method of producing
lab-grown, human-derived tissue to repair the heart after a heart attack.
Specifically, the team grows human heart cells in the lab to produce a scaffold called extracellular matrix and then removes the cells.
The extracellular matrix could be injected into damaged part of the heart to encourage growth and repair, a significantly less invasive procedure than a heart transplant, Morgan wrote in his application. Morgan’s team will focus on determining the optimal conditions to produce extracellular matrix with the proper characteristics for testing in rodents and scaling up.
Specifically, the team grows human heart cells in the lab to produce a scaffold called extracellular matrix and then removes the cells.
The extracellular matrix could be injected into damaged part of the heart to encourage growth and repair, a significantly less invasive procedure than a heart transplant, Morgan wrote in his application. Morgan’s team will focus on determining the optimal conditions to produce extracellular matrix with the proper characteristics for testing in rodents and scaling up.
Developing
an EEG-based test for diagnosing lower back pain
Carl
Saab, an associate professor of neurosurgery and neuroscience (research) at
Brown and Rhode Island Hospital, will use his award to apply his objective
EEG-based test for measuring pain to aid in the diagnosis of acute and chronic
low back pain.
Prior research has shown that his EEG-based method works in rodents; his next step is to apply this technology in the clinic to assess different kinds of back pain. Low back pain is the leading cause of disability worldwide, so being able to determine whether a patient’s pain will be short-lived yet acute, or chronic and debilitating and the correct treatment plan for them would be quite useful, Saab wrote in his application.
This may even lead to reducing the over-prescription of opioids.
Prior research has shown that his EEG-based method works in rodents; his next step is to apply this technology in the clinic to assess different kinds of back pain. Low back pain is the leading cause of disability worldwide, so being able to determine whether a patient’s pain will be short-lived yet acute, or chronic and debilitating and the correct treatment plan for them would be quite useful, Saab wrote in his application.
This may even lead to reducing the over-prescription of opioids.
